Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 6,342 shares of the company's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $58.48, for a total value of $370,880.16. Following the sale, the executive vice president now owns 113,878 shares in the company, valued at $6,659,585.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Fady Ibraham Malik also recently made the following trade(s):
- On Wednesday, October 30th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $51.91, for a total value of $378,943.00.
- On Tuesday, October 15th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $54.19, for a total transaction of $395,587.00.
- On Tuesday, October 1st, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $52.10, for a total value of $380,330.00.
- On Tuesday, September 3rd, Fady Ibraham Malik sold 7,384 shares of Cytokinetics stock. The shares were sold at an average price of $57.01, for a total value of $420,961.84.
Cytokinetics Stock Performance
Why buying gold might be a mistake
From DTI | Ad
Something strange just happened with gold.
With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years.
But for now, I'm not rushing to buy gold.
In fact, I'm telling everyone I know to hold off.
Because I believe there’s a far better way to play this upcoming surge.
It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%.
And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock.
I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now.
Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.
If you're interested, check out the recording here while the link's still up.
Shares of Cytokinetics stock opened at $55.96 on Thursday. The company has a 50 day moving average of $54.18 and a 200-day moving average of $55.39. The company has a market cap of $6.60 billion, a PE ratio of -10.40 and a beta of 0.78. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 1-year low of $30.68 and a 1-year high of $110.25.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.09). The business had revenue of $0.46 million during the quarter, compared to analysts' expectations of $1.21 million. The business's quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.35) earnings per share. As a group, equities research analysts forecast that Cytokinetics, Incorporated will post -5.31 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. J.Safra Asset Management Corp increased its holdings in Cytokinetics by 642.3% in the 2nd quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 456 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Cytokinetics by 65.6% in the third quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 238 shares during the period. Blue Trust Inc. raised its holdings in Cytokinetics by 225.9% in the 3rd quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 680 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Cytokinetics during the 3rd quarter worth approximately $54,000. Finally, EntryPoint Capital LLC bought a new stake in Cytokinetics during the 1st quarter worth approximately $74,000.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on CYTK. Royal Bank of Canada initiated coverage on shares of Cytokinetics in a research report on Friday, November 8th. They issued an "outperform" rating and a $80.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Cytokinetics in a report on Friday, October 18th. JMP Securities reiterated a "market outperform" rating and set a $78.00 target price on shares of Cytokinetics in a research note on Wednesday, September 4th. The Goldman Sachs Group downgraded Cytokinetics from a "buy" rating to a "neutral" rating and reduced their price target for the company from $85.00 to $60.00 in a research note on Tuesday, August 13th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $72.00 price objective on shares of Cytokinetics in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $83.67.
Read Our Latest Report on CYTK
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
